Longitudinal bone growth occurs at the growth plate by endochondral ossification. Within the growth plate, chondrocyte proliferation, hypertrophy, and cartilage matrix secretion result in chondrogenesis. The newly formed cartilage is invaded by blood vessels and bone cells that remodel the newly formed cartilage into bone tissue. This process of longitudinal bone growth is governed by a complex network of endocrine signals, including growth hormone, insulin-like growth factor I, glucocorticoid, thyroid hormone, estrogen, androgen, vitamin D, and leptin. Many of these signals regulate growth plate function, both by acting locally on growth plate chondrocytes and also indirectly by modulating other endocrine signals in the network. Some of the local effects of hormones are mediated by changes in paracrine factors that control chondrocyte proliferation and differentiation. Many human skeletal growth disorders are caused by abnormalities in the endocrine regulation of the growth plate. This review provides an overview of the endocrine signals that regulate longitudinal bone growth, their interactions, and the mechanisms by which they affect growth plate chondrogenesis.

Keywords:
Hormones, Growth plate, Longitudinal bone growth, Growth hormone, Insulin-like growth factor, Glucocorticoid, Thyroid hormone, Estrogen, Androgen, Vitamin D
1.
Kember NF: Cell population kinetics of bone growth: the first ten years of autoradiographic studies with tritiated thymidine. Clin Orthop 1971;76:213–230.
2.
Abad V, Meyers JL, Weise M, Gafni RI, Barnes KM, Nilsson O, Bacher JD, Baron J: The role of the resting zone in growth plate chondrogenesis. Endocrinology 2002;143:1851–1857.
3.
Hunziker EB: Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech 1994;28:505–519.
4.
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623–628.
5.
Farnum CE, Wilsman NJ: Cellular turnover at the chondro-osseous junction of growth plate cartilage: analysis by serial sections at the light microscopical level. J Orthop Res 1989;7:654–666.
6.
Stevens DG, Boyer MI, Bowen CV: Transplantation of epiphyseal plate allografts between animals of different ages. J Pediatr Orthop 1999;19:398–403.
7.
Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, Cutler GB Jr: Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology 1994;135:1367–1371.
8.
Gafni RI, Weise M, Robrecht DT, Meyers JL, Barnes KM, De Levi S, Baron J: Catch-up growth is associated with delayed senescence of the growth plate in rabbits. Pediatr Res 2001;50:618–623.
9.
Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J: Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001;98:6871–6876.
10.
Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Rosenfeld RG: Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139–1147.
11.
Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369–390.
12.
Wit JM, Kamp GA, Rikken B: Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 1996;39:295–302.
13.
Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363–1367.
14.
Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfaffle R, Raile K, Seidel B, Smith RJ, Chernausek SD: IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211–2222.
15.
Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ: A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 1997;94:13215–13220.
16.
Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73–82.
17.
Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ: Somatomedin: proposed designation for sulphation factor. Nature 1972;235:107.
18.
Butler AA, LeRoith D: Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001;142:1685–1688.
19.
Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D: Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002;110:771–781.
20.
Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG: Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997;82:629–633.
21.
Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA: Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000;106:1095–1103.
22.
Isaksson OG, Jansson JO, Gause IA: Growth hormone stimulates longitudinal bone growth directly. Science 1982;216:1237–1239.
23.
Isgaard J, Moller C, Isaksson OG, Nilsson A, Mathews LS, Norstedt G: Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone. Endocrinology 1988;122:1515–1520.
24.
Schlechter NL, Russell SM, Spencer EM, Nicoll CS: Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci USA 1986;83:7932–7934.
25.
Ohlsson C, Nilsson A, Isaksson O, Lindahl A: Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. Proc Natl Acad Sci USA 1992;89:9826–9830.
26.
Isaksson OG, Lindahl A, Nilsson A, Isgaard J: Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987;8:426–438.
27.
Hunziker EB, Wagner J, Zapf J: Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest 1994;93:1078–1086.
28.
Wang J, Zhou J, Bondy CA: Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J 1999;13:1985–1990.
29.
Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di Grezia R, Wedard BM, Angelucci L, Bonucci E: Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 2000;26:33–42.
30.
Chrysis D, Ritzen EM, Savendahl L: Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 2003;176:331–337.
31.
Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, Mehls O: Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 1998;139:3296–3305.
32.
Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB Jr: Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am J Physiol 1992;263:489–492.
33.
Smink JJ, Gresnigt MG, Hamers N, Koedam JA, Berger R, van Buul-Offers SC: Short-term glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J Endocrinol 2003;177:381–388.
34.
Smink JJ, Koster JG, Gresnigt MG, Rooman R, Koedam JA, van Buul-Offers SC: IGF and IGF-binding protein expression in the growth plate of normal, dexamethasone-treated and human IGF-II transgenic mice. J Endocrinol 2002;175:143–153.
35.
Heinrichs C, Yanovski JA, Roth AH, Yu YM, Domene HM, Yano K, Cutler GB Jr, Baron J: Dexamethasone increases growth hormone receptor messenger ribonucleic acid levels in liver and growth plate. Endocrinology 1994;135:1113–1118.
36.
Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab 1994;78:131–137.
37.
Crowley S, Hindmarsh PC, Matthews DR, Brook CG: Growth and the growth hormone axis in prepubertal children with asthma. J Pediatr 1995;126:297–303.
38.
Borges MH, Pinto AC, DiNinno FB, Camacho-Hubner C, Grossman A, Kater CE, Lengyel AM: IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man. J Endocrinol Invest 1999;22:12–17.
39.
Buckler JM, Willgerodt H, Keller E: Growth in thyrotoxicosis. Arch Dis Child 1986;61:464–471.
40.
Leger J, Czernichow P: Congenital hypothyroidism: decreased growth velocity in the first weeks of life. Biol Neonate 1989;55:218–223.
41.
Stevens DA, Hasserjian RP, Robson H, Siebler T, Shalet SM, Williams GR: Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J Bone Miner Res 2000;15:2431–2442.
42.
Miura M, Tanaka K, Komatsu Y, Suda M, Yasoda A, Sakuma Y, Ozasa A, Nakao K: Thyroid hormones promote chondrocyte differentiation in mouse ATDC5 cells and stimulate endochondral ossification in fetal mouse tibias through iodothyronine deiodinases in the growth plate. J Bone Miner Res 2002;17:443–454.
43.
Robson H, Siebler T, Stevens DA, Shalet SM, Williams GR: Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 2000;141:3887–3897.
44.
Ballock R, Mita BC, Zhou X, Chen DH, Mink LM: Expression of thyroid hormone receptor isoforms in rat growth plate cartilage in vivo. J Bone Miner Res 1999;14:1550–1556.
45.
Gauthier K, Chassande O, Plateroti M, Roux JP, Legrand C, Pain B, Rousset B, Weiss R, Trouillas J, Samarut J: Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. EMBO J 1999;18:623–631.
46.
Takeda K, Sakurai A, Degroot LJ, Refetoff S: Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. J Clin Endocrinol Metab 1992;74:49–55.
47.
Kindblom JM, Gothe S, Forrest D, Tornell J, Tornell J, Vennstrom B, Ohlsson C: GH substitution reverses the growth phenotype but not the defective ossification in thyroid hormone receptor alpha 1–/–beta–/– mice. J Endocrinol 2001;171:15–22.
48.
Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [see comments] [published erratum appears in N Engl J Med 1995;332:131]. N Engl J Med 1994;331:1056–1061.
49.
Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Clin Endocrinol Metab 1995;80:3689–3698.
50.
Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743–1748.
51.
Gunther DF, Calikoglu AS, Underwood LE: The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res 1999;46:269–273.
52.
Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH: Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003;143:60–66.
53.
Nilsson O, Falk J, Ritzen EM, Baron J, Savendahl L: Raloxifene acts as an estrogen agonist on the rabbit growth plate. Endocrinology 2003;144:1481–1485.
54.
Zachmann M, Prader A, Sobel EH, Crigler JF Jr, Ritzen EM, Atares M, Ferrandez A: Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986;108:694–697.
55.
Grumbach MM: Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000;13(suppl 6): 1439–1455.
56.
Cutler GB Jr: The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997;61:141–144.
57.
Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr: Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989;320:496–502.
58.
Klein KO, Martha PM Jr, Blizzard RM, Herbst T, Rogol AD: A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay. J Clin Endocrinol Metab 1996;81:3203–3207.
59.
Nilsson O, Chrysis D, Pajulo O, Boman A, Holst M, Rubinstein J, Martin RE, Savendahl L: Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages. J Endocrinol 2003;177:319–326.
60.
Jansson JO, Eden S, Isaksson O: Sites of action of testosterone and estradiol on longitudinal bone growth. Am J Physiol 1983;244:135–140.
61.
Blanchard O, Tsagris L, Rappaport R, Duval-Beaupere G, Corvol M: Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991;40:711–716.
62.
Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C: Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol 2001;171:229–236.
63.
Chagin AS, Lindberg MK, Andersson N, Moverare S, Gustafsson JA, Savendahl L, Ohlsson C: Estrogen receptor-beta inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res 2004;19:72–77.
64.
Oz OK, Millsaps R, Welch R, Birch J, Zerwekh JE: Expression of aromatase in the human growth plate. J Mol Endocrinol 2001;27:249–253.
65.
Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER: Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 1993;76:996–1001.
66.
Phillip M, Maor G, Assa S, Silbergeld A, Segev Y: Testosterone stimulates growth of tibial epiphyseal growth plate and insulin-like growth factor-1 receptor abundance in hypophysectomized and castrated rats. Endocrine 2001;16:1–6.
67.
van der Eerden BC, van Til NP, Brinkmann AO, Lowik CW, Wit JM, Karperien M: Gender differences in expression of androgen receptor in tibial growth plate and metaphyseal bone of the rat. Bone 2002;30:891–896.
68.
Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE: The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997;82:3493–3497.
69.
Ren SG, Malozowski S, Sanchez P, Sweet DE, Loriaux DL, Cassorla F: Direct administration of testosterone increases rat tibial epiphyseal growth plate width. Acta Endocrinol (Copenh) 1989;121:401–405.
70.
Krohn K, Haffner D, Hugel U, Himmele R, Klaus G, Mehls O, Schaefer F: 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 2003;73:400–410.
71.
Maor G, Segev Y, Phillip M: Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle – a model of endochondral ossification. Endocrinology 1999;140:1901–1910.
72.
Dean DD, Boyan BD, Schwart Z, Muniz OE, Carreno MR, Maeda S, Howell DS: Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. Endocrine 2001;14:311–323.
73.
Donohue MM, Demay MB: Rickets in VDR null mice is secondary to decreased apoptosis of hypertrophic chondrocytes. Endocrinology 2002;143:3691–3694.
74.
Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB: Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999;140:4982–4987.
75.
Underwood JL, DeLuca HF: Vitamin D is not directly necessary for bone growth and mineralization. Am J Physiol 1984;246:E493–E498.
76.
Lidor C, Atkin I, Ornoy A, Dekel S, Edelstein S: Healing of rachitic lesions in chicks by 24R,25-dihydroxycholecalciferol administered locally into bone. J Bone Miner Res 1987;2:91–98.
77.
Boyan BD, Sylvia VL, Dean DD, Del Toro F, Schwartz Z: Differential regulation of growth plate chondrocytes by 1alpha,25-(OH)2D3 and 24R,25-(OH)2D3 involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit Rev Oral Biol Med 2002;13:143–154.
78.
Schwartz Z, Ehland H, Sylvia VL, Larsson D, Hardin RR, Bingham V, Lopez D, Dean DD, Boyan BD: 1alpha,25-dihydroxyvitamin D(3) and 24R,25-dihydroxyvitamin D(3) modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase. Endocrinology 2002;143:2775–2786.
79.
Schwartz Z, Pedrozo HA, Sylvia VL, Gomez R, Dean DD, Boyan BD: 1alpha,25-(OH)2D3 regulates 25-hydroxyvitamin D3 24R-hydroxylase activity in growth zone costochondral growth plate chondrocytes via protein kinase C. Calcif Tissue Int 2001;69:365–372.
80.
Vignolo M, Naselli A, Di Battista E, Mostert M, Aicardi G: Growth and development in simple obesity. Eur J Pediatr 1988;147:242–244.
81.
Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG: Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73–78.
82.
Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398–401.
83.
Ozata M, Ozdemir IC, Licinio J: Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999;84:3686–3695.
84.
Maor G, Rochwerger M, Segev Y, Phillip M: Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res 2002;17:1034–1043.
85.
Nakajima R, Inada H, Koike T, Yamano T: Effects of leptin to cultured growth plate chondrocytes. Horm Res 2003;60:91–98.
86.
Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514–520.
87.
Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL: Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 1996;12:88–90.
88.
Wagner JK, Eble A, Hindmarsh PC, Mullis PE: Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr Res 1998;43:105–110.
89.
Domene HM, Bengolea SV, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570–577.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.